

# Antibiotics versus ibuprofen for uncomplicated lower urinary tract infections: a randomised controlled double-blind clinical trial in German general practices

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
10/08/2007	No longer recruiting	<input checked="" type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
04/10/2007	Completed	<input checked="" type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
25/02/2021	Urological and Genital Diseases	

## Plain English summary of protocol

### Background and study aims

Lower urinary tract infections (UTIs) are infections of the bladder or urethra (the tube that carries urine out of the body). They are usually treated with antibiotics. However, there is little evidence for alternative treatment options. The aim of this study is to find out whether the drug ibuprofen is as effective as the antibiotic ciprofloxacin for UTIs.

### Who can participate?

Women aged 18 to 85 with at least one of the main UTI symptoms (painful/difficult or frequent urination)

### What does the study involve?

Participants are randomly allocated to be treated with either ibuprofen or ciprofloxacin, both for three days. The intensity of their symptoms like painful/difficult or frequent urination and low abdominal pain are recorded at the start of the study and after 4, 7 and 28 days, scoring each symptom from 0 (none) to 4 (very strong).

### What are the possible benefits and risks of participating?

Not provided at time of registration

### Where is the study run from?

29 German general practices

### When is the study starting and how long is it expected to run for?

July 2007 to April 2008

### Who is funding the study?

German Federal Ministry of Education and Research (Germany)

Who is the main contact?

Prof. Michael M. Kochen

[mkochen@gwdg.de](mailto:mkochen@gwdg.de)

## Contact information

### Type(s)

Scientific

### Contact name

Prof Michael M. Kochen

### Contact details

Humboldtallee 38

Gottingen

Germany

37075

-

[mkochen@gwdg.de](mailto:mkochen@gwdg.de)

## Additional identifiers

### Protocol serial number

HWI-01

## Study information

### Scientific Title

Antibiotics versus ibuprofen for uncomplicated lower urinary tract infections: a randomised controlled double-blind clinical trial in German general practices

### Study objectives

1. The study demonstrates the feasibility of a randomised controlled double-blind clinical trial in German general practices
2. The results of the ibuprofen group allow the conduction of a larger trial in which the equivalence of ibuprofen and ciprofloxacin in Urinary Tract Infections (UTI) will be tested

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Local ethics committee (Ethikkommission der Universitaetsmedizin Goettingen), 13/06/2007, ref: 8/4/07

### Study design

Randomised controlled double-blind clinical trial

### Primary study design

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Uncomplicated lower urinary tract infection

**Interventions**

There are two intervention arms:

1. Ciprofloxacin 2 x 250 mg for three days (and one placebo per day)
2. Ibuprofen 3 x 400 mg for three days

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Ciprofloxacin, ibuprofen

**Primary outcome(s)**

1. Symptom score on day 4 (symptom score for dysuria, frequency and pain is measured on days 0, 4 and 7 by questionnaire and interviews)
2. Feasibility: descriptive measure, this will be determined by describing the results of:
  - 2.1. Recruitment of General Practitioners (GPs)
  - 2.2. Recruitment of patients
  - 2.3. Number of complete/incomplete data sets

The feasibility will be assessed after the patient recruitment is finished.

**Key secondary outcome(s)**

1. Improvement of symptoms at days 4 and 7
2. Adverse events
3. Number of relapses

The trial duration for each patient is 28 days. The adverse effects and relapses within these 28 days will be concerned. We plan to find out about this by an interview on day 28, and by data collection from GPs data at monitoring visits.

**Completion date**

15/04/2008

## Eligibility

**Key inclusion criteria**

Women with typical symptoms of uncomplicated lower urinary tract infection (dysuria, frequency, lower abdominal pain)

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Female

**Total final enrolment**

79

**Key exclusion criteria**

1. Fever, low back pain
2. Urinary tract infection during the last two weeks
3. Current treatment with antibiotics/Non-Steroidal Anti-Rheumatics (NSAR)
4. Pregnant/breastfeeding women
5. Diabetes
6. Renal diseases
7. Allergy/intolerance to ibuprofen/ciprofloxacin
8. Contraindications for trial medication
9. Severe co-morbidities

**Date of first enrolment**

25/07/2007

**Date of final enrolment**

15/04/2008

## Locations

**Countries of recruitment**

Germany

**Study participating centre**

**Georg-August University of Gottingen**

Gottingen

Germany

37075

## Sponsor information

**Organisation**

Georg-August University of Gottingen (Georg-August-Universitat Gottingen, Universitätsmedizin) (Germany)

ROR

<https://ror.org/01y9bpm73>

## Funder(s)

### Funder type

Government

### Funder Name

Bundesministerium für Bildung und Forschung

### Alternative Name(s)

Federal Ministry of Research, Technology and Space, Bundesministerium für Bildung und Forschung, Federal Ministry of Education and Research, BMBF

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

Germany

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	26/05/2010	25/02/2021	Yes	No
<a href="#">Protocol article</a>	protocol	01/04/2011		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes